Click on image to view larger version.

Figure 3

Fig. 3.

Mechanisms of actions of PKA inhibitors. (A) Rp-cAMPS is a competitive antagonist of the cAMP-binding sites on PKA; binding of Rp-cAMPS to PKA prevents the catalytic subunits from being released. PKI peptide, H89, and KT 5720 all act one stage later. After cAMP binding and catalytic subunit release, PKI peptide binds the catalytic subunits and prevents them from phosphorylating targets. (B) H89 and KT 5720 are both competitive antagonists of the ATP sites on the catalytic subunits; without ATP binding, the catalytic subunits are unable to phosphorylate target proteins. C, protein kinase A catalytic subunit; PKI, protein kinase inhibitor peptide; R, protein kinase A regulatory subunit.

[PowerPoint download feature is available to paid individual subscribers and to registered users at subscribing institutions (register for free).]

You may download the image(s) above for non-profit educational presentation use only, provided no modifications are made to the content. Any use, publication, or distribution of the image(s) beyond that permitted in the sentence above or beyond that allowed by the "Fair Use" limitations (sections 107 and 108) of the US Copyright law requires the prior written permission of AAAS. This permission does not apply to images that are credited to non-AAAS sources. For images credited to non-AAAS entities, you will need to obtain permission from the entity listed in the legend or credit line before making any use of the image(s).